Introduction Mouth and Pharynx to New Technology Group 7 with Fostamatinib, External Approach - XW0DXR7
Introduction Upper GI to New Technology Group 8 with Maribavir Anti-infective, Via Natural or Artificial Opening Approach - XW0G738
Introduction Upper GI to New Technology Group 8 with Sabizabulin, Via Natural or Artificial Opening Approach - XW0G7K8
Introduction Upper GI to New Technology Group 6 with Baricitinib, Via Natural or Artificial Opening Approach - XW0G7M6
Introduction Upper GI to New Technology Group 7 with Fostamatinib, Via Natural or Artificial Opening Approach - XW0G7R7
Introduction Upper GI to New Technology Group 6 with Mineral-based Topical Hemostatic Agent, Via Natural or Artificial Opening Endoscopic Approach - XW0G886
Introduction Lower GI to New Technology Group 8 with Maribavir Anti-infective, Via Natural or Artificial Opening Approach - XW0H738
Introduction Lower GI to New Technology Group 8 with Sabizabulin, Via Natural or Artificial Opening Approach - XW0H7K8
Introduction Lower GI to New Technology Group 6 with Baricitinib, Via Natural or Artificial Opening Approach - XW0H7M6
Introduction Lower GI to New Technology Group 7 with Fostamatinib, Via Natural or Artificial Opening Approach - XW0H7R7
Introduction Lower GI to New Technology Group 8 with Broad Consortium Microbiota-based Live Biotherapeutic Suspension, Via Natural or Artificial Opening Approach - XW0H7X8
Introduction Lower GI to New Technology Group 6 with Mineral-based Topical Hemostatic Agent, Via Natural or Artificial Opening Endoscopic Approach - XW0H886
Introduction Coronary Artery, One Artery to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, One Balloon, Percutaneous Approach - XW0J3HA
Introduction Coronary Artery, One Artery to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Two Balloons, Percutaneous Approach - XW0J3JA
Introduction Coronary Artery, One Artery to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Three Balloons, Percutaneous Approach - XW0J3KA
Introduction Coronary Artery, One Artery to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Four or More Balloons, Percutaneous Approach - XW0J3LA
Introduction Coronary Artery, Two Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, One Balloon, Percutaneous Approach - XW0K3HA
Introduction Coronary Artery, Two Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Two Balloons, Percutaneous Approach - XW0K3JA
Introduction Coronary Artery, Two Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Three Balloons, Percutaneous Approach - XW0K3KA
Introduction Coronary Artery, Two Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Four or More Balloons, Percutaneous Approach - XW0K3LA
Introduction Coronary Artery, Three Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, One Balloon, Percutaneous Approach - XW0L3HA
Introduction Coronary Artery, Three Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Two Balloons, Percutaneous Approach - XW0L3JA
Introduction Coronary Artery, Three Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Three Balloons, Percutaneous Approach - XW0L3KA
Introduction Coronary Artery, Three Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Four or More Balloons, Percutaneous Approach - XW0L3LA
Introduction Coronary Artery, Four or More Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, One Balloon, Percutaneous Approach - XW0M3HA
Introduction Coronary Artery, Four or More Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Two Balloons, Percutaneous Approach - XW0M3JA
Introduction Coronary Artery, Four or More Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Three Balloons, Percutaneous Approach - XW0M3KA
Introduction Coronary Artery, Four or More Arteries to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Four or More Balloons, Percutaneous Approach - XW0M3LA
Introduction Cranial Cavity and Brain to New Technology Group 6 with Eladocagene exuparvovec, Percutaneous Approach - XW0Q316
Introduction Joints to New Technology Group 10 with Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System, Open Approach - XW0U0GA
Introduction Bones to New Technology Group 7 with Antibiotic-eluting Bone Void Filler, Open Approach - XW0V0P7
Introduction Bones to New Technology Group 10 with AGN1 Bone Void Filler, Percutaneous Approach - XW0V3WA
Transfusion Peripheral Vein to New Technology Group 5 with Plasma, Convalescent (Nonautologous), Percutaneous Approach - XW13325
Transfusion Peripheral Vein to New Technology Group 10 with Marnetegragene Autotemcel, Percutaneous Approach - XW1337A
Transfusion Peripheral Vein to New Technology Group 8 with Betibeglogene Autotemcel, Percutaneous Approach - XW133B8
Transfusion Peripheral Vein to New Technology Group 8 with Omidubicel, Percutaneous Approach - XW133C8
Transfusion Peripheral Vein to New Technology Group 7 with High-Dose Intravenous Immune Globulin, Percutaneous Approach - XW133D7
Transfusion Peripheral Vein to New Technology Group 7 with Hyperimmune Globulin, Percutaneous Approach - XW133E7
Transfusion Peripheral Vein to New Technology Group 8 with OTL-103, Percutaneous Approach - XW133F8
Transfusion Peripheral Vein to New Technology Group 8 with OTL-200, Percutaneous Approach - XW133G8
Transfusion Peripheral Vein to New Technology Group 9 with Lovotibeglogene Autotemcel, Percutaneous Approach - XW133H9
Transfusion Peripheral Vein to New Technology Group 8 with Exagamglogene Autotemcel, Percutaneous Approach - XW133J8
Transfusion Central Vein to New Technology Group 5 with Plasma, Convalescent (Nonautologous), Percutaneous Approach - XW14325
Transfusion Central Vein to New Technology Group 10 with Marnetegragene Autotemcel, Percutaneous Approach - XW1437A
Transfusion Central Vein to New Technology Group 8 with Betibeglogene Autotemcel, Percutaneous Approach - XW143B8
Transfusion Central Vein to New Technology Group 8 with Omidubicel, Percutaneous Approach - XW143C8
Transfusion Central Vein to New Technology Group 7 with High-Dose Intravenous Immune Globulin, Percutaneous Approach - XW143D7
Transfusion Central Vein to New Technology Group 7 with Hyperimmune Globulin, Percutaneous Approach - XW143E7
Transfusion Central Vein to New Technology Group 8 with OTL-103, Percutaneous Approach - XW143F8
Transfusion Central Vein to New Technology Group 8 with OTL-200, Percutaneous Approach - XW143G8
Transfusion Central Vein to New Technology Group 9 with Lovotibeglogene Autotemcel, Percutaneous Approach - XW143H9
Transfusion Central Vein to New Technology Group 8 with Exagamglogene Autotemcel, Percutaneous Approach - XW143J8
Insertion Mouth and Pharynx to New Technology Group 7 with Neurostimulator Lead, Via Natural or Artificial Opening Approach - XWHD7Q7
Monitoring Central Nervous to New Technology Group 9 with Brain Electrical Activity, Computer-aided Detection and Notification, External Approach - XX20X89
Monitoring Circulatory to New Technology Group 10 with Blood Flow, Adhesive Ultrasound Patch Technology, External Approach - XX25X0A
Monitoring Musculoskeletal to New Technology Group 9 with Muscle Compartment Pressure, Micro-Electro-Mechanical System, Percutaneous Approach - XX2F3W9
Monitoring Subcutaneous Tissue to New Technology Group 9 with Interstitial Fluid Volume, Sub-Epidermal Moisture using Electrical Biocapacitance, External Approach - XX2KXP9
Assistance Circulatory to New Technology Group 10 with Filtration, Blood Pathogens, Percutaneous Approach - XXA536A
Measurement Central Nervous to New Technology Group 7 with Intracranial Vascular Activity, Computer-aided Assessment, External Approach - XXE0X07
Measurement Central Nervous to New Technology Group 10 with Intracranial Cerebrospinal Fluid Flow, Computer-aided Triage and Notification, External Approach - XXE0X1A
Measurement Central Nervous to New Technology Group 8 with Brain Electrical Activity, Computer-aided Semiologic Analysis, External Approach - XXE0X48
Measurement Cardiac to New Technology Group 9 with Output, Computer-aided Assessment, External Approach - XXE2X19
Measurement Arterial to New Technology Group 7 with Pulmonary Artery Flow, Computer-aided Triage and Notification, External Approach - XXE3X27
Measurement Arterial to New Technology Group 8 with Coronary Artery Flow, Quantitative Flow Ratio Analysis, External Approach - XXE3X58
Measurement Arterial to New Technology Group 8 with Coronary Artery Flow, Computer-aided Valve Modeling and Notification, External Approach - XXE3X68
Measurement Circulatory to New Technology Group 10 with Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum, External Approach - XXE5X2A
Measurement Circulatory to New Technology Group 8 with Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction, External Approach - XXE5X38
Measurement Circulatory to New Technology Group 10 with Infection, Positive Blood Culture Small Molecule Sensor Array Technology, External Approach - XXE5X4A
Measurement Circulatory to New Technology Group 6 with Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility, External Approach - XXE5XN6
Measurement Circulatory to New Technology Group 7 with Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure, External Approach - XXE5XR7
Measurement Circulatory to New Technology Group 7 with Intracranial Arterial Flow, Whole Blood mRNA, External Approach - XXE5XT7
Measurement Circulatory to New Technology Group 7 with Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection, External Approach - XXE5XV7
Measurement Circulatory to New Technology Group 9 with Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology, External Approach - XXE5XY9
Measurement Nose to New Technology Group 7 with Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction, Via Natural or Artificial Opening Approach - XXE97U7
Measurement Respiratory to New Technology Group 6 with Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection, External Approach - XXEBXQ6
Introduction Vein Graft to New Technology Group 3 with Endothelial Damage Inhibitor, External Approach - XY0VX83
Introduction Extracorporeal to New Technology Group 8 with Taurolidine Anti-infective and Heparin Anticoagulant, External Approach - XY0YX28
Introduction Extracorporeal to New Technology Group 7 with Nafamostat Anticoagulant, External Approach - XY0YX37
